Previous 10 | Next 10 |
Updated results from a dataset of 43 patients showed durable responses and stable disease greater than six months with inupadenant monotherapy in five patients with advanced solid tumors, including previously reported confirmed partial responses in patients with checkpoint-inhibitor...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 26, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, toda...
iTeos Therapeutics, Inc. (ITOS) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Ryan Baker – Head of Investor Relations Michel Detheux – President and Chief Executive Officer Joe Lager – Chief Medical Officer Matthew Gall – Chief Finan...
iTeos Therapeutics (ITOS): Q1 GAAP EPS of -$0.39 beats by $0.09.Cash and cash equivalents of $321.4M as of March 31, 2021, compared to $147.7M as of March 31, 2020. The cash balance provides a runway into 2023.Press Release For further details see: iTeos Therapeutics EPS beats by $...
- Presented differentiated clinical and pharmacodynamic data from Phase 1/2a trial of anti-TIGIT antibody, EOS-448, at AACR 2021; expansion into combination cohorts expected mid-2021 - - Inupadenant updated monotherapy clinical data and evidence of association of A 2A ...
CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 06, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, toda...
Esperion sheds nearly a third on Stifel cut Esperion Therapeutics (ESPR) has lost ~32.8% in the early hours after Stifel downgraded the stock to hold from buy noting “we don't think this story gets any better soon.”Esperion’s Q1 2021 financials came be...
CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, toda...
The first week of AACR 2021 (American Association of Cancer Research Annual Meeting) has concluded with Affimed (AFMD) emerging as a clear winner while iTeos Therapeutics (ITOS) disappointed with an early-stage study for its lead asset.The presentations from Eli Lilly (LLY), Oncternal Therape...
News, Short Squeeze, Breakout and More Instantly...
iTeos Therapeutics Inc. Company Name:
ITOS Stock Symbol:
NASDAQ Market:
iTeos Therapeutics Inc. Website:
WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today a...
2024-05-22 01:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-13 07:00:04 ET Swayampakula Ramakanth from H.C. Wainwright issued a price target of $46.00 for ITOS on 2024-05-13 06:11:00. The adjusted price target was set to $46.00. At the time of the announcement, ITOS was trading at $17.44. ITOS currently trades -32.51% ver...